Table 2 TEAEs in > 20% of patients receiving ripretiniba
Preferred term, n (%) | Ripretinib (n = 85) | Placebo (n = 43) | ||
|---|---|---|---|---|
All grades | Grade 3–4 | All grades | Grade 3–4 | |
Alopecia | 44 (52) | N/A | 2 (4.7) | N/A |
Fatigue | 36 (42) | 3 (3.5) | 10 (23) | 1 (2.3) |
Nausea | 33 (39) | 3 (3.5) | 5 (12) | 0 |
Abdominal pain | 31 (37) | 6 (7.1) | 13 (30) | 2 (4.7) |
Constipation | 29 (34) | 1 (1.2) | 8 (19) | 0 |
Myalgia | 27 (32) | 1 (1.2) | 5 (12) | 0 |
Diarrhea | 24 (28) | 1 (1.2) | 6 (14) | 1 (2.3) |
Decreased appetite | 23 (27) | 1 (1.2) | 9 (21) | 1 (2.3) |
PPESb | 18 (21) | 0 | 0 | 0 |
Vomiting | 18 (21) | 3 (3.5) | 3 (7.0) | 0 |